Kristina Jankovic, MD· @JankovicK · X·· 16 hours agoScore60
Body
@OncoAlert 🚨 4Sights Abstracts to be presented at #ESMO26 🇪🇸 | #evERA: Promising biomarker insights after CDK4/6i! In patients with ER+/HER2- advanced #BreastCancer in the post CDK 4/6i setting giredestrant + everolimus demonstrated greater PFS benefit 🆚 SOC endocrine therapy + everolimus, regardless of ctDNA tumor fraction, with benefit observed across ESR1 variants and poor-prognosis molecular subgroups 👇
Heat 0 · 0 likes · 0 replies · 0 reposts
Conference abstracts
NCT05113251NCT05113251matched by - **æ ‡é¢˜ / Title：** Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- **æ ‡é¢˜ / Title：** Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerRead the abstract →Source: Kristina Jankovic, MD · x.com